Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). Methods In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12. Secondary endpoints included objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was monitored.
INTRODUCTION
Ankylosing spondylitis (AS), also called radiographic axial spondyloarthritis (axSpA), is a chronic systemic inflammatory disease of the axial skeleton with major impact on quality of life. 1 The management of AS comprises physical therapy alongside non-steroidal anti-inflammatory drugs (NSAIDs), followed by tumour necrosis factor inhibitors (TNFi) for persistent disease. [2] [3] [4] [5] No evidence exists for efficacy of conventional synthetic diseasemodifying antirheumatic drugs (DMARDs) for treating axial disease. 3 Recently, secukinumab, an interleukin (IL)-17 blocker, became available as a treatment for AS, 6 but treatment options remain limited. 6 7 Therefore, an unmet need exists for therapies with alternative mechanisms of action to control and manage radiographic axSpA. 8 Tofacitinib is an oral Janus kinase ( JAK) inhibitor. Through direct and indirect inhibition of cytokine pathways, tofacitinib can modulate immune responses and reduce or prevent inflammation. 9 In cellular settings, tofacitinib preferentially inhibits signalling via JAK3 and/or JAK1 with functional selectivity over signalling via pairs of JAK2. 10 11 This affects signalling via IL-17, IL-21 and IL-23, 9 12 which have been implicated in AS pathology [13] [14] [15] and antibodies to IL-17 have demonstrated efficacy in AS. 6 16 In addition, tofacitinib reduced serum levels of TNF 9 and TNFi have been found to be efficacious in the treatment of active AS. 3 Extra-articular manifestations associated with AS include inflammatory diseases such as psoriasis, inflammatory bowel disease and uveitis. 17 The efficacy and safety of tofacitinib have been studied in several immune-mediated inflammatory diseases, such as rheumatoid arthritis, [18] [19] [20] [21] [22] [23] psoriasis 24-26 and ulcerative colitis. 27 28 Results of the first proofof-concept dose-ranging investigation of the effects of tofacitinib in adult patients with active AS are reported. This study also represents the first dose-ranging study in AS.
METHODS
This was a 16-week (12- week treatment, 4-week washout), phase II, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study (NCT01786668) to investigate the efficacy, safety and dose response of tofacitinib in patients with active AS.
Patients
Patients entering the study were ≥18 years of age and fulfilled the modified New York (mNY) criteria for AS, confirmed by centralised reading of sacroiliac (SI) radiographs. Patients had active disease based on Bath AS Disease Activity Index (BASDAI) score ≥4 and back pain score ≥4 and history of either inadequate response to ≥2 oral NSAIDs or intolerance to prior NSAIDs. Patients with C reactive protein (CRP) levels within the normal reference range and those with active arthritis, enthesitis or psoriasis could be enrolled, provided mNY criteria for AS were met. Patients were permitted to
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Sample size was determined by clinical trial simulations using the Emax model to estimate true ASAS20 responders at week 12 with different doses. Simulations were conducted under several plausible truths, assuming 50 patients per treatment group (200 in total). If the true placebo-corrected ASAS20 response in the range 1-10 mg twice daily was 20%-40%, the estimated placebo-corrected effect for that dose with limits ±10% was projected to capture the true placebo-corrected response rate ≥83% of the time.
Binary secondary endpoints were analysed using the normal approximation. Continuous endpoints were analysed as change from baseline with a marginal repeated measure model including treatment group, visit, treatment group-by-visit interaction and baseline value as fixed effects.
Safety data were summarised descriptively.
Subanalyses
Post hoc subanalyses were performed to identify whether baseline CRP or MRI status impacted efficacy (ASAS20 and ASAS40; online supplementary section 4).
RESULTS
Between April 2013 and March 2015, 445 patients were screened, with 208 patients randomised and 207 treated (1 patient randomised to placebo did not receive study medication; figure 1 ). Of these, 196 patients completed the study; 51 placebo-treated patients and 52 in each tofacitinib group were included in analyses (figure 1). Of the 237 patients who failed screening, 67 patients did not meet radiological criteria (figure 1). Baseline demographics and disease characteristics were generally similar between groups and typical of an active AS population (table 1) . ASAS20 response rates using NRI at week 12 ( primary endpoint) for placebo and tofacitinib 2, 5 and 10 mg twice daily are shown in table 2. According to the Emax model, the predicted 10 mg dose response rate was 67.4%; 11.4% and 27.3% higher than the tofacitinib 2 mg twice daily and placebo rates, respectively. As per normal approximation for comparing active treatment with placebo, response rates were significantly greater with tofacitinib 5 mg twice daily versus placebo ( p<0.001), but not with tofacitinib 2 or 10 mg twice daily.
Secondary and other efficacy endpoint responses at week 12 are presented in table 3. All tofacitinib groups had ASAS40 and BASDAI50 response rates and change in ASDAS of similar magnitude, and were significant versus placebo. All tofacitinib groups had statistically significant improvement from baseline in BASDAI versus placebo. ASAS5/6 response rates were significantly greater with tofacitinib 5 and 10 mg twice daily versus placebo. ASDAS clinically important improvement response rates were significantly higher in all tofacitinib groups versus placebo; ASDAS major response was not significantly different between tofacitinib and placebo. ASDAS low/moderate disease was significantly higher with tofacitinib 2 and 5 mg twice daily versus placebo while there was no significant difference between treatment groups for ASDAS inactive disease. Tofacitinib 5 and 10 mg twice daily demonstrated significant improvement versus placebo in SPARCC SI joint scores, while all tofacitinib doses had significant improvement versus placebo in SPARCC spine scores (figure 2). Tofacitinib 5 and 10 mg twice daily demonstrated significant improvement versus placebo in Berlin scores 0.41; p<0.001 and p=0.001, respectchange from baseline CRP values at oss all groups. dpoints at other study visits are prementary table S1 or figure 2 (including response rate over time is presented in figure S1. Numerical separation from b doses was observed for all endpoints AS inactive disease, where the response ups (<10%). patients with enthesitis at baseline, tofae daily demonstrated statistically signifis placebo at week 12 in change from online supplementary figure S2). unts and mean chest expansion at each all groups (see online supplementary acitinib experienced greater improve-EQ-5D mobility, SF-36 physical compoily pain, FACIT-F, ASQoL and work upplementary table S3). ated that patients with high (≥0.287 mg/ rmal in the central laboratory)) baseline ent effect with tofacitinib versus placebo .287 mg/dL) baseline CRP (ASAS20 and plementary table S4). This is especially inly due to a lower placebo response in ne CRP. For patients with positive baseint cut-off ≥2 at baseline), greater treated with all doses of tofacitinib versus tofacitinib 5 mg twice daily (ASAS20 5 mg twice daily vs placebo ( p<0.001); <0.01)) (see online supplementary table t effect (ASAS20 and ASAS40) by com-I status demonstrated that tofacitinibhigh CRP/MRI-positive subgroup had at week 12 versus placebo compared her (see online supplementary table S6). uld be interpreted with caution due to s in the various subgroups. fety summary. More patients reported (TEAEs) with tofacitinib 5 and 10 mg twice daily than tofacitinib 2 mg twice daily and placebo (53.8% and 51.9% vs 44.2% and 43.1%, respectively; online supplementary table S7). Overall, the most frequently reported TEAEs were nasopharyngitis (n=13) and upper respiratory tract infection (n=8). One cardiovascular AE (hypertension) was reported with tofacitinib 10 mg twice daily. Two treatmentrelated herpes zoster cases were reported (one each with tofacitinib 2 and 10 mg twice daily; online supplementary section 4). One serious infection event of chronic iridocyclitis (uveitis) was reported (tofacitinib 5 mg twice daily); however, an infective process was not confirmed. This was considered to be a chronic event unrelated to study treatment and resolved following treatment with intravenous antibiotics and glucocorticoids. No other serious infections or cases of tuberculosis, malignancy, gastrointestinal perforation or death were reported.
Dose-dependent changes in laboratory outcomes were observed and returned to approximately baseline values by week 16, following the 4-week washout period. Only one patient had laboratory values meeting discontinuation criteria: a confirmed pregnancy in the placebo group.
DISCUSSION
This was the first proof-of-concept dose-ranging study of tofacitinib in patients with AS and the first dose-ranging study in AS. A noteworthy aspect of this study was the use of central reading to confirm radiographic sacroiliitis as an entry criterion for the first time in a clinical trial of AS; therefore, it represents the most homogenous patient population with AS in a randomised clinical study to date. Approximately 15% of patients considered suitable for entry into this study by local investigator failed screening due to not meeting the radiological criteria after central read. This highlights the variation of radiological scoring by individual study investigators and suggests that central reading could benefit future study designs to ensure consistency in patients included based on radiographic sacroiliitis.
An Emax model was used to estimate the dose-response relationship for the ASAS20 response rate. The modelling predicted that at week 12, tofacitinib 5 and 10 mg twice daily had ASAS20 response rates of 63.0% and 67.4%, respectively. Normal approximation analysis demonstrated that tofacitinib 5 mg twice daily was the only tofacitinib dose statistically superior to placebo for the ASAS20 response rate at week 12; this could reflect on. AE, adverse event. sampling variability. Tofacitinib 10 mg twice daily was numerically better than placebo but the difference was not statistically significant by normal approximation. Results based on such a model in a phase II proof-of-concept study are used during clinical development of an investigational product in relation to the a priori go/no go decision to initiate a phase III study. Overall efficacy data, excluding ASAS20, generally demonstrated significant improvement with tofacitinib 5 and 10 mg twice daily versus placebo over 12 weeks of treatment across most endpoints assessed, with minimal clinical difference between the two tofacitinib doses. Tofacitinib 2 mg twice daily also demonstrated significantly superior efficacy versus placebo in ASAS40 and ASDAS endpoints, except ASAS5/6. Separation from placebo was observed by week 8 in most secondary endpoints, except ASAS20, ASAS40 and ASAS5/6, which separated at week 4. This appears to suggest slower onset of efficacy compared with TNFi. 29-32 However, comparing data across studies is challenging due to differences in patient populations and study design. Absolute ASAS20, ASAS5/6, ASAS40 and BASDAI50 week 12 response rates for tofacitinib doses in this study appear generally similar to those reported for TNFi in phase III studies in AS populations, although these studies reported lower placebo responses than we observed, particularly for ASAS20 and BASDAI50. [30] [31] [32] The placebo response observed in this study was high; the reason for this is currently unknown, but does not appear to relate to differences in gender or geographical region. It is known that male patients with AS often experience better improvement in outcomes versus females; however, fewer male patients were enrolled in the placebo group compared with the tofacitinib groups. ASAS responses appeared consistent across geographical regions (data not shown), although small patient numbers in some groups limit any interpretation. One potential explanation may be the inclusion of patients with no objective other efficacy endpoint responses at week 12 signs of inflammation, for example, patients could be enrolled if they had normal CRP levels; however, this accounted for few patients. Subanalyses by baseline CRP/MRI status indicated that patients with high baseline CRP had a better response with tofacitinib versus placebo than those with low CRP. In this study, the 5 mg twice daily arm had the highest number of patients with high CRP and baseline MRI inflammation. In the composite analysis, high CRP/positive MRI at baseline were associated with higher ASAS response rates in all tofacitinib groups versus placebo than subgroups with lower baseline CRP/negative MRI. Similar results have been reported for TNFi in an AS cohort, where high baseline CRP was a predictor of better treatment response. 33 Moreover, a greater treatment effect in patients with positive MRI and/or elevated CRP is especially seen in studies of TNFi in patients with non-radiographic axSpA, 34 35 while there are only limited data in patients with AS. 36 Overall, we found that objective measures, such as SPARCC SI joint and spine scores and BASMI, demonstrated a dose response, while more subjective endpoints, including PROs, did not. Subjective endpoints can be influenced by many factors affecting the patient, not all of which may be drug related. It is also possible that subjective improvement in symptoms lags behind improvement in objective assessments. It may also be that ASAS20 is not sufficiently discriminatory and therefore no longer represents the preferred endpoint for assessing treatment effect, especially given the high placebo response, which is also observed in other trials. 37 38 Other endpoints, such as ASDAS or ASAS40, may be more suitable as primary outcome measures. However, a combination of assessments, including subjective and objective measures such as imaging, may be needed to evaluate overall disease improvement in early development.
The pattern of AEs and changes in laboratory outcomes were similar to those reported in previous tofacitinib studies in other indications. 18-27 39-44 Laboratory test outcomes returned to approximately baseline values by week 16, following the 4-week washout period, which is also consistent with observations in other indications and may be important if patients require treatment withdrawal.
One limitation of our study was the 12-week duration of active treatment. The duration was chosen based on onset of efficacy observed in previous tofacitinib clinical trials in other indications, while balancing patient safety with a limited exposure time. It is possible that a maximum efficacy response was not reached by week 12.
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